Skip to content

Salivary Fluoride Clearance

Evaluation of Salivary Fluoride Clearance Following the Use of Three MFP-Containing Dentifrices

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06735235
Enrollment
27
Registered
2024-12-16
Start date
2021-07-14
Completion date
2021-07-29
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caries

Brief summary

This is a single-center, four-treatment, four-period crossover study. Over the course of the study, up to thirty qualified subjects will use four (4) study treatment products, one time each according to the randomization. Subjects will brush with 1.25g of the assigned study product at each visit. Subjects will provide saliva samples at baseline and at 2, 6, 12, and 30 minutes post-treatment. The F- concentrations in each saliva sample will be determined by ion chromatography

Interventions

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Sponsors

Procter and Gamble
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Be at least 18 years of age; * Provide written informed consent prior to study participation and be given a signed copy of the Informed Consent form; * Be in good general health as determined by the Investigator/Designee based on a review of their medical history; * Have at least 16 natural teeth; * Have normal salivary flow (0.3-0.6 ml/min) or deemed acceptable by the Investigator/Designee as determined in a previous screening outside of this protocol; * Agree not to participate in any other oral care studies for the duration of this study; * Agree not to change their current oral care routine except 1) to refrain from using mouth rinse and 2) to agree to use study washout product as designated (current floss users are permitted to continue to floss during this study); viii. Agree to delay elective dentistry, including dental prophylaxis, until study completion, and to report any non-study dentistry received during the course of the study; * Agree to refrain from eating, using breath mints, using medicated lozenges, chewing gum, brushing their teeth or drinking within 2 hours of the visit, other than small sips of water up to 30 minutes prior to the visit; * Agree to refrain from drinking tea or mineral water, and/or eating sardines within the 12 hours prior to the study visit; and * Agree to return for all scheduled visits and to follow all study procedures.

Exclusion criteria

* Active treatment for gingivitis, periodontitis, or caries; * Self-reported pregnancy or nursing; * Smoking or tobacco chewing; * Sjögren syndrome or any other disease/condition causing severe xerostomia; * Kidney disease or renal impairment; * Undergoing chemotherapy or irradiation procedures; * Fixed orthodontic appliances that may interfere with product use; * Inability to undergo any study procedures; or * Any condition or disease, as determined by the Investigator/Designee that could be expected to interfere with examination procedures or with the subject's safe completion of the study

Design outcomes

Primary

MeasureTime frameDescription
area under the curve (AUC)2-minutes, 6-minutes, 12-minutes, and 30-minutesThe primary endpoint will be AUC of the fluoride levels from 2 to 30 minutes. AUC will be calculated for each subject and treatment combination by integrating a 3 parameter first order decay model curve estimate (y= theta1 \* exp (-theta2.X) + theta3). For any values obtained for a timepoint that are below the detection limit, 0.5 times the detection limit will be used. The following rules will apply if a subject has missing value(s) before the AUC is calculated: * If 2 or more timepoints are missing within a period, then the AUC will be set to missing * If only 2-minute data are missing, then curve will be estimated as above * If 6-minute or 12-minute data are missing, a linear imputation between the adjacent timepoints will be used * If 30-minute data are missing, the 12-minute data will be carried forward.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026